Literature DB >> 9390009

Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature.

C Pihoker1, T M Badger, G A Reynolds, C Y Bowers.   

Abstract

Growth hormone-releasing peptide (GHRP)-2 is a synthetic six amino acid peptide that is a potent GH secretagogue. Although it shares no structural homology with GH-releasing hormone, in clinical studies its actions on the pituitary release of GH are similar. It is effective when administered orally and intranasally. For children with GH deficiency, such noninvasive treatments are most desirable and in need of development. Fifteen children with short stature participated in this study. All of the children had a height < 2 S.D. below mean for age, poor height velocity, delayed bone age, and low serum concentrations of IGF-1. These children had been tested with standard GH secretagogues, e.g. arginine, insulin, and L-dopa. Fifty percent of the children were GH deficient, the remainder had idiopathic short stature. The children received testing with GHRH and GHRP-2 as an acute i.v. bolus of 1 microgram/kg; all children in this study demonstrated a GH response > 20 micrograms/l. Each child in this study also demonstrated a GH response > 10 micrograms/l in response to intranasal GHRP-2, in the dose range of 5-20 micrograms/kg. The children were administered intranasal GHRP-2, 5-15 micrograms/kg, twice a day for 3 months, then three times a day. Fifteen children participated in the study for 6 months; six of the children have participated for 18-24 months. Height velocity, serum IGF-1, IGF-binding protein 3 (IGFBP-3) and GH-binding protein (GHBP) concentrations, and GH responses to GHRP-2 by i.v. bolus and intranasal spray were examined during treatment. Height velocity increased from 3.7 +/- 0.2 cm/year to 6.1 +/- 0.3 cm/year at 6 months, 6.0 +/- 0.4 cm/year at 18-24 months. There were no significant changes in IGF-1 or IGF-PB3 concentrations, or in acute GH responses to i.v. or intranasal GHRP-2. GHBP concentrations rose significantly, from 439 +/- 63 pmol/l to 688 +/- 48 pmol/l. In this study, intranasal GHRP-2 administration was well tolerated, and produced a modest but significant increase in growth velocity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9390009     DOI: 10.1677/joe.0.1550079

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  10 in total

Review 1.  The Safety and Efficacy of Growth Hormone Secretagogues.

Authors:  John T Sigalos; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2017-04-08

2.  Integrating GHS into the Ghrelin System.

Authors:  Johannes D Veldhuis; Cyril Y Bowers
Journal:  Int J Pept       Date:  2010-03-18

3.  Estrogen elevates the peak overnight production rate of acylated ghrelin.

Authors:  Remberto C Paulo; Richard Brundage; Mihaela Cosma; Kristi L Mielke; Cyril Y Bowers; Johannes D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2008-08-12       Impact factor: 5.958

4.  Development of a Predictive Enrichment Marker for the Oral GH Secretagogue LUM-201 in Pediatric Growth Hormone Deficiency.

Authors:  George M Bright; Minh-Ha T Do; John C McKew; Werner F Blum; Michael O Thorner
Journal:  J Endocr Soc       Date:  2021-02-25

Review 5.  Effects of growth hormone and its secretagogues on bone.

Authors:  J Svensson; S Lall; S L Dickson; B A Bengtsson; J Rømer; I Ahnfelt-Rønne; C Ohlsson; J O Jansson
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.925

6.  Increased Secretion of Endogenous GH after Treatment with an Intranasal GH-releasing Peptide-2 Spray Does Not Promote Growth in Short Children with GH Deficiency.

Authors:  Toshiaki Tanaka; Yukihiro Hasegawa; Susumu Yokoya; Yoshikazu Nishi
Journal:  Clin Pediatr Endocrinol       Date:  2014-11-06

7.  Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation.

Authors:  Rui Hu; Zhisheng Wang; Quanhui Peng; Huawei Zou; Hongze Wang; Xiaoqiang Yu; Xiaoping Jing; Yixin Wang; Binghai Cao; Shanke Bao; Wenhua Zhang; Suonan Zhao; Hanzhong Ji; Xiangying Kong; Quanxi Niu
Journal:  PLoS One       Date:  2016-02-19       Impact factor: 3.240

8.  Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.

Authors:  John T Sigalos; Alexander W Pastuszak; Andrew Allison; Samuel J Ohlander; Amin Herati; Mark C Lindgren; Larry I Lipshultz
Journal:  Am J Mens Health       Date:  2017-08-22

Review 9.  From Belly to Brain: Targeting the Ghrelin Receptor in Appetite and Food Intake Regulation.

Authors:  Ken Howick; Brendan T Griffin; John F Cryan; Harriët Schellekens
Journal:  Int J Mol Sci       Date:  2017-01-27       Impact factor: 5.923

Review 10.  Treatment of Pediatric Growth Hormone Deficiency With Oral Secretagogues Revisited.

Authors:  Mabel Yau; Robert Rapaport
Journal:  J Endocr Soc       Date:  2021-05-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.